Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Medchemexpress LLC Molnupiravir | 2492423-29-5 | 99.9% | 329.31 | 200 MG
SDP

Catalog No. 5000366051
Encompass_Preferred

Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. It exhibits broad-spectrum antiviral activity against influenza virus and multiple coronaviruses, including SARS-CoV-2, MERS-CoV, and SARS-CoV. It is being researched for its potential use in COVID-19 and seasonal/pandemic influenza.

  • Orally bioavailable prodrug
  • Exhibits broad-spectrum antiviral activity
  • Effective against SARS-CoV-2, MERS-CoV, and SARS-CoV
  • Being researched for use in COVID-19 and influenza
  • Prevents SARS-CoV replication in C57BL/6 mice
  • Reduces shed virus load and fever duration in ferrets

Catalog No. 50-003-66051 Supplier Medchemexpress LLC Supplier No. 200MGHY135853
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. It exhibits broad-spectrum antiviral activity against influenza virus and multiple coronaviruses, including SARS-CoV-2, MERS-CoV, and SARS-CoV. It is being researched for its potential use in COVID-19 and seasonal/pandemic influenza.

  • Orally bioavailable prodrug
  • Exhibits broad-spectrum antiviral activity
  • Effective against SARS-CoV-2, MERS-CoV, and SARS-CoV
  • Being researched for use in COVID-19 and influenza
  • Prevents SARS-CoV replication in C57BL/6 mice
  • Reduces shed virus load and fever duration in ferrets

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.